European Antibiotic Awareness Day (EAAD) 2020
EAAD will be marked on Wednesday 18 November 2020, in partnership with WHO’s World Antibiotic Awareness Week (18-24 November 2020).
Antimicrobial resistance and consumption remains high in the EU/EEA and the UK, according to new ECDC data
New data released today by ECDC show that levels of antimicrobial resistance and antimicrobial consumption in the EU/EEA and the UK are still of concern, particularly in the southern and eastern parts of Europe. ECDC is today launching its 2020 digital campaign to further raise awareness among health professionals and the public of the importance of continuing the fight against antimicrobial resistance to preserve the effectiveness of antimicrobials.
Annual updates on antibiotic resistance and antibiotic consumption
On the occasion of EAAD 2020 ECDC releases its annual update on antibiotic resistance and antibiotic consumption surveillance data from EU/EEA countries.
Due to the COVID-19 pandemic, EAAD will this year be marked with a digital campaign, in partnership with the World Antimicrobial Awareness Week (WAAW), during the week of 18-24 November 2020, with a special focus on 18 November with the theme:
“In times of COVID-19, don’t give up on antimicrobial resistance (AMR) and stay united to preserve antimicrobials”.
As part of the European Antibiotics Awareness Day (EAAD) digital campaign, ECDC has collated a series of filmed statements by high-level stakeholders from the European Commission and the German presidency of the Council of the European Union, as well as experts. Each video addresses a number of key issues in relation to antimicrobial resistance. The videos will be released and promoted on social media in connection with EAAD on 18 November under the hashtags #EAAD and #KeepAntibioticsWorking.
Social media campaign
On Wednesday 18 November, at 15.00 CET, ECDC and organisations from around the globe will tweet about #AntibioticResistance and #WAAW. Post through your Twitter account at that time or during the day!Find out more
Get involved on social media
Find our online channels, add hashtags, use our frames, or take part in the Facebook/Twitter live. Find all you need for your social media communication, join the action and spread the news!Get involved
Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance?
"The COVID-19 pandemic reminds us that compliance with IPC measures is critical to ensure the safety of hospitalised patients. Most IPC measures that are essential for controlling the spread of SARS-CoV-2 also contribute to reducing the spread of antimicrobial-resistant bacteria; these, together with antimicrobial stewardship programmes, must be maintained and strengthened. In the midst of the COVID-19 pandemic, we certainly must not give up on our efforts to prevent and control AMR and must stay united to preserve the effectiveness of antimicrobials."
Translated campaign materials
Facts and infographics on antimicrobial resistance in healthcare settings based on the last-year point prevalence surveys in all EU/EEA languages.
Helstu skilaboðin: Notkun á sýkingalyfjum á vettvangi heilbrigðisþjónustunnar
Á árunum 2016-2017, samræmdi Sóttvarnastofnun Evrópu (ECDC) aðra útbreiðslukönnunina á tilteknum tímapunkti á sýkingum sem tengjast heilbrigðisþjónustu og notkun á sýkingalyfjum á evrópskum bráðasjúkahúsum og þriðju útbreiðslukönnunina á tilteknum tímapunkti á sýkingum sem tengjast heilbrigðisþjónustu og notkun á sýkingalyfjum á evrópskum dvalarheimilum.Nánari upplýsingar
Íþyngjandi áhrif sýklalyfjaónæmis á heilsufar
Á hverju ári deyja 33.000 manns þar sem bein orsök er sýkingar þar sem bakteríurnar eru ónæmar fyrir sýklalyfjum. Þetta er sambærilegt við fjölda farþega í meira en 100 miðlungsstórum flugvélum.Nánari upplýsingar
Sýkingar sem tengjast heilbrigðisþjónustu – ógn við öryggi sjúklinga í Evrópu
Talið er að samanlagt 8,9 milljónir sýkinga sem tengjast heilbrigðisþjónustu komi upp á hverju ári samanlagt á evrópskum sjúkrahúsum og dvalarheimilum.
Sýklalyfjanotkun á: Langtíma umönnunstöðum
7 af 10 sýkingalyfjum voru ávísuð til meðferðar á sýkingu og 3 af 10 sem fyrirbyggjandi meðferð.
Notkun örverueyðandi lyfja í evrópskum sjúkrahúsum og langtíma umönnunarstofnunum
1 af 3 sjúklingum fékk að minnsta kosti eitt örverueyðandi lyf á hverjum degi.Nánari upplýsingar